| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Despite of considerable advances in multimodality therapy, the overall 5-year survival rate for patients with hypopharyngeal squamous cell carcinoma (HSCC) is ranging from 30-40%. To date, there is no effective treatment resumes for patients with recurrence and distant metastasis of HSCC. Our recent study of microRNA (miRNA) expression signature of HSCC showed that miR-504 was significantly reduced in cancer tissues. Ectopic expression of miR-504 markedly suppressed cancer cell proliferation. To identify the molecular targets of miR-504, cell cycle-related genes were selected as target genes of miR-504. The expression of cyclin-dependent kinase 6 (CDK6) was significantly higher in HSCC tissues compared to non-cancer tissues. Expression of miR-504 inhibited CDK6 expression in HSCC cells. The identification of target oncogenes regulated by miR-504 might lead to a better understanding of HSCC pathogenesis the development of new therapeutic strategies to treat this disease.
|
